Skip to content

Study for protein expression of the complement activation product C4a in patient plasma of non-small cell lung cancer of different clinical stages

Study for protein expression of the complement activation product C4a in patient plasma of non-small cell lung cancer of different clinical stages

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023962
Enrollment
Unknown
Registered
2019-06-19
Start date
2019-02-25
Completion date
Unknown
Last updated
2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1 Inclusion criteria of patients with non-small cell lung cancer: (1) Participants who are dignosed as stage I or IV non-small cell lung cancer by pathological or cytological methods; (2) Aged 30~80; (3) ECOG score: 0-3, KPS=50; (4) Participants have signed informed consent and have good compliance. 2. Inclusion criteria of non-cancer controls: (1) Participants who are not diagnosed as cancer; (2) Aged 30~80 years; (3) Participants have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria of patients with non-small cell lung cancer: (1) Participants who have received immunoenhancer or immunosuppressant half a month before sampling; (2) Participants who have received radiotherapy and chemotherapy half a month before sampling; (3) Participants who are diagnosed as severe recurrent diseases (such as autoimmune diseases and leukemia); (4) Participants who are diagnosed as microbial (including bacterial, viral and mycoplasma infection) infection; (5) Participants who have received blood transfusion one year before sampling. 2. Exclusion criteria of non-cancer controls: (1) Participants who are diagnosed as severe recurrent diseases (such as autoimmune diseases and leukemia); (2) Participants who are diagnosed as microbial (including bacterial, viral and mycoplasma infection) infection; (3) Participants who received blood transfusion one year before sampling.

Design outcomes

Primary

MeasureTime frame
APTT/PT/TT/FIB;C4a level in plasma;

Countries

China

Contacts

Public ContactWeidong Zhang

Shanghai University of Traditional Chinese Medicine

wdzhangy@hotmail.com+86 021-81871244

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026